Growth hormone axis
Tesamorelin
Synthetic GHRH analogue
Licensed GHRH analogue that reduces visceral fat in HIV-associated lipodystrophy
- Body composition
- Longevity
- +2
- WADA prohibited
£255 · In stock
In the range · Tesamorelin
Directory · 32 compounds
32 compounds graded the same way — 21 of them are in the AERVYN range, carried by 24 pre-filled pens (4 of them blends). Each is assessed on one structured record: human evidence for every goal it has been researched for, regulatory status taken from our maintained database rather than inferred, published dosing research, safety and interactions. Where a compound is in the range — on its own pen or inside a blend — the card names the pen and its price.
Showing 32 of 32
Growth hormone axis
Synthetic GHRH analogue
Licensed GHRH analogue that reduces visceral fat in HIV-associated lipodystrophy
£255 · In stock
In the range · Tesamorelin
Longevity & mitochondrial
Mitochondrial-derived 16-amino-acid peptide
Mitochondrial 'exercise mimetic' peptide: mouse data only, WADA-prohibited
£255 · In stock
In the range · MOTS-C
Skin, hair & cosmetic
Copper-binding tripeptide
Topical copper peptide with modest cosmetic data; injectable use is untested
£215 · In stock
In the range · GHK-Cu
Longevity & mitochondrial
Coenzyme (not a peptide)
Endogenous coenzyme; the human trials are of oral precursors, not injected NAD+
£285 · In stock
In the range · NAD+
Tissue repair
Synthetic pentadecapeptide
Widely sold 'healing peptide' with animal data but no published human trials
£170 · In stock
In the range · BPC-157
Tissue repair
Synthetic thymosin β4 fragment (residues 17–23)
Thymosin β4 fragment sold for healing; no human trials of the fragment
£180 · In stock
In the range · TB-500
Immune
Anti-inflammatory tripeptide (α-MSH fragment)
α-MSH tripeptide with anti-inflammatory animal data and no human trials
£175 · In stock
In the range · KPV
Metabolic (incretin-based)
GIP/GLP-1/glucagon receptor triple agonist
Investigational triple agonist with the largest trial weight loss reported so far
£370 · In stock
In the range · Retatrutide (R3T)
Metabolic (incretin-based)
Long-acting amylin analogue
Investigational weekly amylin analogue, studied alone and with semaglutide (CagriSema)
£360 · In stock
In the range · CagriSema (blend)
Metabolic (incretin-based)
GLP-1 receptor agonist
Once-weekly incretin medicine with the largest weight-management evidence base
£265 · In stock
In the range · Semaglutide
Growth hormone axis
Long-acting GHRH analogue (albumin-binding)
Long-acting GHRH analogue abandoned in development; sold as a research chemical
£180 · In stock
In the range · CJC-1295 (no DAC)
Longevity & mitochondrial
Synthetic pineal-derived tetrapeptide
'Telomerase-activating' longevity peptide with no controlled human trials
£220 · In stock
In the range · Epitalon
Longevity & mitochondrial
FOXO4–p53 interfering peptide (D-retro-inverso)
Designed senolytic peptide that rejuvenated aged mice; no human data of any kind
£330 · In stock
In the range · FOXO4-DRI
Sexual health
Gonadotropin-releasing hormone (GnRH) decapeptide
Native GnRH: a licensed pituitary test and pump therapy, compounded off-label with testosterone
£200 · In stock
In the range · Gonadorelin
Growth hormone axis
Selective ghrelin-receptor agonist (GH secretagogue pentapeptide)
Selective GH secretagogue that failed its only published efficacy trial
£175 · In stock
In the range · Ipamorelin
Metabolic (incretin-based)
GLP-1 receptor agonist
Once-daily GLP-1 medicine with a decade of use and generic versions
£235 · In stock
In the range · Liraglutide
Immune
Human cathelicidin antimicrobial peptide (37 amino acids)
Human antimicrobial peptide: topical wound trials only, injected use untested
£200 · In stock
In the range · LL-37
Sexual health
Melanocortin-4 receptor agonist
FDA-approved on-demand injection for low sexual desire in premenopausal women
£195 · In stock
In the range · PT-141
Growth hormone axis
GHRH(1–29) fragment (growth-hormone-releasing hormone analogue)
Formerly licensed GHRH fragment, now compounded for adult use with little evidence
£190 · In stock
In the range · Sermorelin
Immune
Immunomodulatory thymic peptide (28 amino acids)
Immune-modulating peptide medicine abroad; weak evidence for wellness use
£210 · In stock
In the range · Thymosin Alpha-1
Metabolic (incretin-based)
Dual GIP/GLP-1 receptor agonist
Once-weekly dual incretin with the largest weight loss among authorised medicines
£320 · In stock
In the range · Tirzepatide
Growth hormone axis
Recombinant human growth hormone
Prescription growth hormone: proven for deficiency, weak and risky for enhancement
Not in the AERVYN range
Metabolic (incretin-based)
Dual glucagon/GLP-1 receptor agonist
Investigational weekly glucagon/GLP-1 dual agonist in phase 3 for obesity and MASH
Not in the AERVYN range
Skin, hair & cosmetic
Oral hydrolysed collagen (food supplement)
Oral food supplement with modest randomised-trial evidence for skin and joints
Not in the AERVYN range
Cognition, mood & sleep
Synthetic tuftsin-analogue heptapeptide
Russian intranasal anxiolytic peptide with small, unreplicated trials
Not in the AERVYN range
Cognition, mood & sleep
Synthetic ACTH-fragment heptapeptide
Russian intranasal 'nootropic' peptide; stroke data unreplicated abroad
Not in the AERVYN range
Longevity & mitochondrial
Mitochondria-targeting tetrapeptide (cardiolipin binder)
Mitochondrial peptide approved for one rare disease; negative trials elsewhere
Not in the AERVYN range
Sexual health
Hypothalamic neuropeptide (KISS1 receptor agonist)
Investigational reproductive hormone studied for low desire and IVF, not a medicine
Not in the AERVYN range
Sexual health
Non-selective melanocortin receptor agonist (α-MSH analogue)
Unlicensed tanning and libido peptide that regulators have publicly warned against
Not in the AERVYN range
Cognition, mood & sleep
Endogenous neuropeptide (nonapeptide)
1970s 'sleep peptide' with small, inconsistent human studies and no modern trials
Not in the AERVYN range
Growth hormone axis
Synthetic C-terminal fragment of human growth hormone
Failed obesity drug candidate now sold without authorisation; WADA-prohibited
Not in the AERVYN range
Growth hormone axis
Engineered IGF-1 analogue (laboratory reagent)
Laboratory IGF-1 analogue with no human trials and serious hypoglycaemia risk
Not in the AERVYN range